Wanbury has announced that its active pharmaceutical ingredient (API) manufacturing facility in Patalganga has received the Certificate of Good Manufacturing Practices (CBPF) from ANVISA, the Brazilian Health Regulatory Agency.

This follows the GMP approval granted to Wanbury’s Tanuku facility in Andhra Pradesh earlier this month, on May 12, 2025.

The certification for the Patalganga plant was awarded after ANVISA reviewed the U.S. FDA inspection report and other supporting documents submitted by the company. Based on the evaluation, ANVISA confirmed that the facility meets its regulatory standards.

With this latest certification, both of Wanbury’s API manufacturing sites are now fully compliant with ANVISA's regulatory requirements.